BASF and Eight Partners Cooperate to Optimize Production Processes for Renewable-Based Products
A consortium of companies in the European process industry from the areas of biotechnology, renewable resources, chemistry, process engineering, equipment supply, as well as research organizations recently launched project PRODIAS (PROcessing Diluted Aqueous Systems). The project focuses on unlocking the potential of renewable-based products made via white biotechnology, by significantly decreasing production costs, increasing productivity and efficiency, lowering energy consumption, and accelerating process developments.
Under the consortial leadership of BASF, the partners include Cargill Haubourdin, France; University of Kaiserslautern, Germany; Imperial College London, UK; Alfa Laval, Sweden; GEA Messo PT, the Netherlands; Xendo, the Netherlands; UPM, Finland; and Enviplan, Germany. These partners will collaborate to develop cost and energy-efficient technologies for water purification, removal and product-recovery needed to support downstream processing in white biotechnology.
Using biotechnological methods such as fermentation or biocatalysis, in most cases the renewable-based products are produced as part of complex dilute aqueous mixtures from which they have to be purified. This includes the removal of a vast amount of water, making the downstream process energy intensive as it often requires many complex consecutive separation steps and thus hampers the cost-competitiveness of products from renewable resources. Furthermore, processing methods developed for chemical production are often used which are insufficiently adapted to biotechnological processes.
PRODIAS aims to address these challenges by developing and implementing cost-effective separation and purification technologies tailored for renewable resources in white biotechnology production processes. Its focus is to adapt separation techniques to the need of white biotechnology products and to design novel hybrid systems combining individual advantages, for example, selectivity and energy efficiency. The bioreactions (fermentations) and biocatalysis by which the valuable products are produced are subject to alteration and optimization, to enable more efficient and resource-saving downstream processing.
The total project budget is about €14 million with the European Union contributing €10 million. EU funding of the PRODIAS project is enabled via the Public-Private Partnership with SPIRE (Sustainable Process Industry through Resource and Energy Efficiency). SPIRE, in turn, is part of Horizon 2020, the EU framework program for research and innovation, which runs from 2014 to 2020 and comprises an €80 billion budget. In partnership with industry, the EU will invest in innovative technologies for sustainable processes.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance